CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans

Thomas-Pfaab, Marianne; Annereau, Jean‐Philippe; Munsch, C.; Guilbaud, Nicolas; Garrido, I.; Paul, C.; Brousset, Pierre; Lamant, Laurence; Meyer, Nicolas

doi:10.1016/j.jdermsci.2012.11.003

Cited by 18 publications

(21 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For MM, Carrel et al 16)17) showed CD10 expression in 63% and 38% of ocular and cutaneous tumor tissues, respectively. Kianitakis et al 6) found that frequency of CD10 expression in MMs was higher in metastatic lesions in skin (69.0%) or lymph nodes (61.0%) than in primary tumors (21.4%), in accordance with several other reports [7][8][9] . These results suggest a close relationship between up-regulation of CD10 and tumor progression in MM.…”

Section: Discussionsupporting

confidence: 82%

“…Representative melanocytic markers, including S100, HMB-45, and melan-A, are often used in diagnosing melanocytic lesions; although they are useful for MM and tumors with melanocytic differentiation 3) , their use in distinguishing malignant and benign melanocytic lesions is limited 3) . CD10 expression can reportedly predict aggressiveness of MM [6][7][8][9] . CD10 is a cell surface glycoprotein expressed in both normal and neoplastic cells, including follicular lymphoma 10) , renal cell carcinoma 11) , endometrial stromal sarcoma 11)12) , atypical fibroxanthoma 13) , and many benign or malignant tumors 11)13) , although the precise function of CD 10 in each tumor is still not fully understood 14) .…”

Section: Introductionmentioning

confidence: 99%

“…CD10 is a cell surface glycoprotein expressed in both normal and neoplastic cells, including follicular lymphoma 10) , renal cell carcinoma 11) , endometrial stromal sarcoma 11)12) , atypical fibroxanthoma 13) , and many benign or malignant tumors 11)13) , although the precise function of CD 10 in each tumor is still not fully understood 14) . CD10 expression in MM was first described by 9 Jongeneel et al 15) using flow cytometry in cell lines. Carrel et al 16)17) then showed CD10 expression in vivo in MM tissues by IHC; several other reports have significantly correlated CD10 expression levels with tumor progression 6)8) [18][19][20] .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunohistochemical CD10 Expression is Useful for Differentiating Malignant Melanoma from Benign Melanocytic Nevus

Hoshikawa

Koizumi

Handa

et al. 2015

J St. Marianna Univ

View full text Add to dashboard Cite

Malignant melanoma (MM), an aggressive skin neoplasm, can be difficult to differentiate histologically from benign melanocytic nevi (BMN). Although immunohistochemical analysis could facilitate diagnosis of MM, markers that discriminate between benign and malignant lesions have not yet been established. However, CD10 expression is associated with MM progression. We immunostained 36 MM and 50 BMN specimens for CD10 to evaluate whether CD10 immunostaining could distinguish between BMN and MM tumors. In the 36 MM samples, we found CD10 expression in 17 (47.2%) sample tumor cells and 32 (88.9%) stromal cells, for 34 of the 36 MM specimens (94.4%) overall. In contrast, no BMN (0/50) samples had CD10 + tumor cells, although a few (8/50, 16.0%) showed stromal staining. The two specimen types thus significantly differed in CD10 expression (P<0.01), indicating that melanocytic CD10 + tumor cells are likely to be malignant. Also, melanocytic stromal cells with diffuse, strong CD10 expression are more likely to be malignant than those with light, focal CD10 expression. Although hematoxylin and eosin staining is fundamental to the diagnosis of melanocytic lesions, CD10 immunostaining may help distinguish between BMN and MM.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical CD10 Expression is Useful for Differentiating Malignant Melanoma from Benign Melanocytic Nevus

Hoshikawa

Koizumi

Handa

et al. 2015

J St. Marianna Univ

View full text Add to dashboard Cite

show abstract

“…However, it was reported that, although nestin was more highly expressed in melanoma than in nevi, there was no statistically significant difference [9,10]. Compared with CD10, nestin is less significantly correlated with prognosis [11]. Furthermore, nestin is not a prognostic indicator for desmoplastic melanoma [12].…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of nestin in primary malignant melanoma of the oral cavity

Kuk

Won²,

Lee³

et al. 2016

Melanoma Research

View full text Add to dashboard Cite

Several studies have examined the correlation between nestin expression and the degree of tumor invasion in cutaneous melanoma. However, no information has been reported on nestin in primary mucosal melanoma of the head and neck. The present study examined the expression and prognostic significance of nestin in patients with primary mucosal melanoma of the oral cavity. Nestin expression was examined immunohistochemically in 39 patients (six oral melanoma in-situ cases and 33 invasive oral melanoma cases) and analyzed for association with disease progression. Age, sex, anatomic site, stage, level of invasion, regional lymph node metastasis, surgical margin involvement, and treatment modality were also analyzed. In the 33 invasive melanoma cases, invasion depth correlated significantly with prognosis in univariate and multivariate analyses. High-intensity nestin staining was observed in 14 of the 33 cases and a high proportion of nestin-positive cells was observed in 16 cases. In stage III oral melanoma cases, nestin expression was not significantly associated with disease progression. However, in stage IV cases, both the intensity and the proportion of nestin expression were significantly associated with disease progression (P=0.022 and 0.005, respectively). In all 33 invasive cases, multivariate analyses showed that both the intensity and the proportion of nestin were significantly associated with a poor prognosis (P=0.014 and 0.009; hazard ratio, 3.59 and 4.05; 95% confidence interval, 1.29-9.98 and 1.42-11.56, respectively). In conclusion, nestin can be a valuable prognostic indicator in the advanced-stage (stage IV) cases of oral mucosal melanoma.

show abstract

“…neutral endopeptidase and/or neprilysin), and legumain (EC 3.4.22.34; syn. asparaginyl endopeptidase) (33)(34)(35)(36). However, on the basis of only few current data, their usefulness as biomarkers still is difficult to estimate.…”

Section: Other Enzyme Markersmentioning

confidence: 99%

Biomarkers in Malignant Melanoma: Recent Trends and Critical Perspective

Belter

Haase-Kohn

Pietzsch

2017

Cutaneous Melanoma: Etiology and Therapy

View full text Add to dashboard Cite

Abstract:The worldwide incidence of malignant melanoma is steadily increasing, suggesting a probable melanoma "epidemic." From a clinical point of view, malignant melanoma still is an unpredictable disease and, once in the advanced stage, allows only scarce therapeutic options. There is an urgent need to identify, characterize, and validate informative biomarkers, biomarker patterns, or surrogate markers in order to not only improve early diagnosis of melanoma but also for differential diagnosis, staging, prognosis, therapy selection, and therapy monitoring. In this chapter, an update on the ongoing debate on serologic and histologic markers such as lactate dehydrogenase, tyrosinase, S100 family of calcium-binding proteins, cyclooxygenase-2, matrix metalloproteinases, and stem and/or progenitor cell markers are presented, and novel, innovative, and promising trends currently being explored are discussed.

show abstract

CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans

Cited by 18 publications

References 23 publications

Immunohistochemical CD10 Expression is Useful for Differentiating Malignant Melanoma from Benign Melanocytic Nevus

Immunohistochemical CD10 Expression is Useful for Differentiating Malignant Melanoma from Benign Melanocytic Nevus

Prognostic significance of nestin in primary malignant melanoma of the oral cavity

Biomarkers in Malignant Melanoma: Recent Trends and Critical Perspective

Contact Info

Product

Resources

About